Mercator Therapeutics and Pepscan Therapeutics Establish Research and Licensing Collaboration

06-Jan-2011 - Netherlands

Mercator Therapeutics and Pepscan Therapeutics announced a multi-program research collaboration. The companies will collaborate to optimize Mercator’s ‘Homing Peptides’ using Pepscan’s proprietary CLIPS technology.

Mercator’s Homing Peptides are discovered through a unique in vivo screening process, including screening in consenting end-stage cancer patients. These peptides have been demonstrated in vivo to bind to receptors that are highly expressed on human tumors and induce internalization of both the peptide and the receptor. Pepscan’s CLIPS technology will be applied to improve the potency and stability of peptides by locking the peptides into the biologically active conformation.

Under the terms of the Research and License Agreement between Mercator and Pepscan, Pepscan will increase the potency and stability of Mercator’s Homing Peptides and license to Mercator the associated intellectual property rights. Mercator will pay Pepscan undisclosed research funding, milestones, and royalties in connection with the development of optimized Homing Peptides and the development and commercialization of PDC products that couple optimized Homing Peptides with tumor-killing payloads.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances